BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cheal SM, Chung SK, Vaughn BA, Cheung NV, Larson SM. Pretargeting: A Path Forward for Radioimmunotherapy. J Nucl Med 2022;63:1302-15. [DOI: 10.2967/jnumed.121.262186] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
Number Citing Articles
1 Aboagye EO, Barwick TD, Haberkorn U. Radiotheranostics in oncology: Making precision medicine possible. CA Cancer J Clin 2023. [PMID: 36622841 DOI: 10.3322/caac.21768] [Reference Citation Analysis]
2 Albertsson P, Bäck T, Bergmark K, Hallqvist A, Johansson M, Aneheim E, Lindegren S, Timperanza C, Smerud K, Palm S. Astatine-211 based radionuclide therapy: Current clinical trial landscape. Front Med (Lausanne) 2022;9:1076210. [PMID: 36687417 DOI: 10.3389/fmed.2022.1076210] [Reference Citation Analysis]
3 Lugat A, Bailly C, Chérel M, Rousseau C, Kraeber-Bodéré F, Bodet-Milin C, Bourgeois M. Immuno-PET: Design options and clinical proof-of-concept. Front Med (Lausanne) 2022;9:1026083. [PMID: 36314010 DOI: 10.3389/fmed.2022.1026083] [Reference Citation Analysis]